Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 17 Jul 2015

GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

In outbreak situations such as the Ebola crisis, vaccines play an essential role that was largely needed during the 2014 health emergency, especially when the plague reached the First World. To ensure preparedness against Ebola, now and in the future, companies have been rushing to develop vaccines against this disease. GSK has come up with […]

July 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Jul 2015

Imperial Innovations receives a €71M loan from the European Investment Bank

Imperial Innovations secured another loan facility from the European Investment Bank (EIB) to support the company’s investments in the UK biotech and life science sector. This €71.3M (£50 million) funding follows a previous €42.9M (£30 million) loan granted by the EIB in July 2013. The European Investment Bank, which last year provided €13.3Bn to enhance […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Jul 2015

Sanofi’s Extreme Makeover gives prominence to Genzyme

There seems to be a tendency towards revolution amongst Sanofi’s CEOs. Olivier Brandicourt, Managing director of the French drugmaker since his €4.1M golden handshake with the company, has come up with a restructuration plan that will reduce Sanofi’s business units from seven to five. The French businessman expects this reorganization will help the company to […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jul 2015

Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo

A new success for personalized medicines against cancer! AstraZeneca and Qiagen’s collaboration has achieved a major milestone after receiving the FDA’s approval of Iressa, a first-line treatment for a common form of lung cancer. The drug candidate is paired with Qiagen’s therascreen EGRF test as a companion diagnostic test. There is no doubt: the future […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jul 2015

GSK becomes the first Pharma to collaborate with the Francis Crick Institute

The future Francis Crick Institute has established its first industrial collaboration, even before opening its doors. And the lucky nominee couldn’t have been any other than GlaxoSmithKline, the UK’s largest pharmaceutical company. The partners are seeking to better understand human diseases, hoping that the research will lead to innovative drugs against a broad range of disorders. The […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Jul 2015

Probiodrug bets on basic research with Harvard’s collaboration

Probiodrug will provide research funding to the laboratory of Cynthia Ann Lemere in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical School. Dr. Lemere is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s disease. […]

July 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Jul 2015

Researchers found the missing key factor to unleash the potential of iPS Cells

When the Nobel Prize-winning Dr. Shinya Yamanaka succeeded to generate induced pluripotent cells (iPS cells) from specialized adult cells, the field of stem cells was completely revolutionized. Since Yamanaka’s paper on adult mouse fibroblasts back in 2006, scientists have been able to perform cellular reprogramming, but the process still isn’t mastered yet. One of the […]

July 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Jul 2015

After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

Horizon Pharma is getting anxious and has offered the substantial amount of €2.7Bn to buy its American competitor Depomed. The Irish drug-maker plans to add the US-based firm to its shopping list just after enrolling Hyperion Therapeutics, the company that was purchased only one month ago. Dublin-based Horizon has been pursuing Depomed lately, but the American company is playing […]

July 13, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 10 Jul 2015

First-in-human successful Phase I for an Alzheimer’s vaccine

AXON Neuroscience has completed a pioneer Phase I that offers new hope for millions of patients with Alzheimer’s disease. This makes AXON the first company to successfully complete this clinical trial for a vaccine that targets diseased tau proteins, which cause neural degeneration. Alzheimer’s disease is characterized by the presence of prejudicial forms of protein […]

July 10, 2015 - 2 minutesmins - By Lourdes Riquelme

eye Bayer Healthcare Johns Hopkins University

News and Trends 9 Jul 2015

Vision specialist Gensight eyes a €90M IPO on NASDAQ

French Gensight intends to raise one of the biggest European IPOs on the American stock market. The gene-therapy specialist will pursue €90.6M to advance with two early-stage candidates for orphan eyes diseases. Gensight will travel across the Ocean to look for the same success its compatriots had on the American stock market. The company will […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jul 2015

Oasmia anticipates an Oncology market growth and seeks €23M on NASDAQ

Human and veterinary oncologist Oasmia files for a €23M IPO on the American NASDAQ. The Swedish company, anticipating an increase in the oncology field, seeks to increase its visibility and to establish itself in the US. The papers have been sent, Oasmia Pharmaceutical will go to NASDAQ under the symbol OAX. The Swedish company was […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Jul 2015

Genmab and Novartis look for the European approval of their leukemia candidate

Genmab is seeking the European authorization for Arzerra, a treatment co-developed with Novartis. The submission is based on the candidate’s positive results in its Phase III in patients with leukemia. Arzerra, the commercial name for ofatumumab, is a human monoclonal antibody that directs the body’s immune system to fight normal and cancerous B-lymphocytes. The drug […]

July 8, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us